spacer
home > pmps > spring 2017 > supply and demand
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supply and Demand

The R&D of a new molecular entity (NME) is a constant battle and requires tradeoffs between the budget set by the organisation, product development goals, personnel available and the public health issues of the country. The total worldwide R&D expenditure of pharmaceutical and biotechnology companies increased from $108 billion in 2006 to $141 billion in 2015. Paul et al reported that:
  • Drug discovery and preclinical development account for 33% of the total cost per NME ($281 million)
  • Clinical development (Phase 1 to submission) represents 63% ($548 million)
  • Submission to launch costs 5% of the overall expenditures per NME ($44 million)
Discovery research lasts four and a half years; preclinical testing continues for a further year; the three clinical development phases take 1.5, 2.5 and 2.5 years respectively; and the phase from submission to launch requires another 18 months. The above is a clear testimonial of the significance of the whole clinical research process that accounts for the majority of the cost and time involved in bringing an innovation to market.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
With over 19 years of clinical research experience in global project management and CTS, Partha Chatterjee is Head of Clinical Research and Clinical Trial Supplies Management at SIRO Clinpharm. A postgraduate in Microbiology from the Institute of Science, India, he was one of the earliest members of the company and his knowledge and expertise have been pivotal in managing numerous key clinical trials across therapeutic areas such as oncology, nephrology, endocrinology and infectious diseases.
spacer
Partha Chatterjee
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harbouring Exon 20 Insertion Mutations

BEERSE, BELGIUM, May 18, 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 1 CHRYSALIS study evaluating amivantamab (JNJ-6372) in the treatment of patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion mutations.[i] Amivantamab is an EGFR and MET-targeted bispecific antibody, which targets activating and resistance EGFR mutations, and MET pathway activation.[ii],[iii] Investigators assessed efficacy using overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), duration of response, as well as the safety profile of amivantamab,1 which were the basis of the U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation granted earlier this year.[iv]
More info >>

White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement